Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C

M. Persico, M. Capasso, R. Russo, E. Persico, L. Crocè, C. Tiribelli, A. Iolascon

Research output: Contribution to journalArticle

Abstract

Background: The response to antiviral therapy of chronic hepatitis C virus (HCV) infection is determined by virological, environmental and genetic factors. Objective: The hypothesis was tested that the expression of specific genes and their haplotype frequencies can differentiate between non-responders (NRs) and sustained virological responders (SVRs) to antiviral treatment. Methods: A methodological approach based on molecular marker discovery and validation was used to study the genes influencing the antiviral treatment in lymphoblastoid cell lines from 74 genotype 1b HCV patients (44 from Southern Italy and 30 from Northern Italy) treated with pegylated interferon (IFN) α and ribavirin. Furthermore, an association study was performed, testing three single nucleotide polymorphisms (SNPs) of suppressor of cytokine signalling 3 (SOCS3) in 162 NR and 184 SVR subjects (SOCS3 -8464 A/C (rs12952093), -4874 A/G (rs4969170) and 1383 A/G, (rs4969168)). Results: SOCS3 basal expression levels were significantly increased in two independent sets of NR groups (p

Original languageEnglish
Pages (from-to)507-515
Number of pages9
JournalGut
Volume57
Issue number4
DOIs
Publication statusPublished - Apr 2008

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C'. Together they form a unique fingerprint.

  • Cite this

    Persico, M., Capasso, M., Russo, R., Persico, E., Crocè, L., Tiribelli, C., & Iolascon, A. (2008). Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut, 57(4), 507-515. https://doi.org/10.1136/gut.2007.129478